RxDoctor Payments DataLook up a doctor →

Anthony Joseph, MD

Retina Specialist · Tucson, AZNPI 1780900845

Payments from drug & device makers

$121,542in general payments, 2019–2025

Across 188 payments — averaging $646.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nidek CO., LTD.$100K
  • AbbVie$12K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Alimera Sciences, Inc.$1K
  • Genentech, Inc.$1K
  • Alcon Research LLC$923
  • plus $4K from 15 others
$2,694in research payments, 2019–2025

Across 1 payment — averaging $2693.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Consulting fees$9,87846%
  • Travel & lodging$3,22115%
  • Food & beverage$8,30839%
  • Education$470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$121,542 in reported general payments places this provider in the 60th percentile of 30 retina specialist providers in Arizona.

See all retina specialist providers in Arizona

Medicare billing

Part B allowed, 2024
$4,772,235
Medicare patients
1,333
Services billed
47,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate245$12,157
ProlensaBromfenac Sodium26$11,665
Bromfenac Sodium53$7,842
Ketorolac Tromethamine144$2,759
Difluprednate23$1,953
Ofloxacin115$1,242
Dorzolamide Hcl54$789
Brimonidine Tartrate38$729
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat28$464
Atropine Sulfate12$427
ErythromycinErythromycin Base28$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$42$11,66526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 30 retina specialist providers in Arizona.

Other retina specialist in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →